US Appeals Court Rules in Favor of Novo Nordisk and Eli Lilly on Weight-Loss Drug Compounding Restrictions

A federal appeals court upheld the FDA's classification of specific diabetes and obesity drugs, effectively restricting the ability of compounding pharmacies to produce generic versions under shortage exemptions. This ruling protects the market exclusivity of Novo Nordisk and Eli Lilly's high-demand GLP-1 products by limiting legal pathways for copycat manufacturing.